Nuformix plc (LON:NFX – Get Free Report) was down 18% during mid-day trading on Friday . The company traded as low as GBX 0.08 ($0.00) and last traded at GBX 0.08 ($0.00). Approximately 10,914,796 shares traded hands during trading, a decline of 86% from the average daily volume of 76,368,313 shares. The stock had previously closed at GBX 0.10 ($0.00).
Nuformix Stock Performance
The company has a market cap of £1.01 million, a P/E ratio of -2.49 and a beta of 1.22. The stock has a 50 day moving average price of GBX 0.06 and a 200 day moving average price of GBX 0.09.
Nuformix (LON:NFX – Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Recommended Stories
- Five stocks we like better than Nuformix
- 5 Top Rated Dividend Stocks to Consider
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- What is the Dow Jones Industrial Average (DJIA)?
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
